Aurobindo Pharma entirely owned subsidiary business enterprise, Eugia Pharma Specialities received a final approval from america Food & Drug Administration (USFDA) to
manufacture and market Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial, which is bioequivalent and therapeutically equal to the reference listed drug (RLD), Mozobil Injection, 24 mg/1.2 mL (20 mg/mL) of Genzyme Corporation. The product is being launched in July FY24. The permitted product has an estimated marketplace length of round US$ 210 million for the 12 months finishing May 2023.